Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.38 |
| ▸ | CES1 | P23141 | 11/20 | 0.37 |
| ▸ | CES2 | O00748 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492542 | 0.79 | ALDH1A1 (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3628918 | 0.79 | CPA1 (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL27044758 | 0.77 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL19501033 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL19501022 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL30358256 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL13864005 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL26302474 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL8793317 | 0.75 | FAAH (0.38) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL894768 | 0.73 | CPA1 (0.43) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865213-B2 | Max binders as MYC modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190144466-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865213-B2 | Max binders as MYC modulators and uses thereof | MYC, MYCBP, MYCBP2 | FAAH 4884/4885CES1 4391/4885CES2 4218/4885 |
| US-20190144466-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | FAAH 4884/4885CES1 4391/4885CES2 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.